DAIICHI SANKYO COMPANY,LIMITED (4568.T) Latest Company News

Sep 17, 2026, 13:30 UTC
The National Institute for Health and Care Excellence (NICE) issued a positive recommendation for reimbursement in England of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as monotherapy for adults with unresectable or metastatic HER2 Low breast cancer.
Source:
- rttnews.com
Sep 16, 2026, 12:30 UTC
Fortis Healthcare filed a special leave petition in the Supreme Court against a Delhi High Court order dated August 31 directing a forensic audit into alleged asset erosion by its former promoters during Daiichi Sankyo's enforcement proceedings.
Source:
- business-standard.com
Sep 10, 2026, 09:58 UTC
The Tokyo District Court dismissed all claims by an IHH Healthcare subsidiary seeking about 203.3 billion yen in damages from Daiichi Sankyo over a halted tender offer for an Indian healthcare company.
Source:
- nikkei.com
- economictimes.indiatimes.com
Sep 2, 2026, 09:17 UTC
Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.
Source:
- nikkei.com
Sep 2, 2026, 04:52 UTC
Daiichi Sankyo announced that the European Union granted a partial change approval for the combination therapy of Enhertu and pertuzumab as first-line treatment for breast cancer patients.
Source:
Aug 31, 2026, 13:00 UTC
The Delhi High Court ordered a forensic audit into the dissipation of Fortis shares and assets linked to former Fortis promoters Malvinder Mohan Singh and Shivinder Mohan Singh in the Daiichi Sankyo enforcement case, appointing S Ramanand Aiyar & Co. as the forensic auditor.
Source:
Aug 27, 2026, 01:04 UTC
Daiichi Sankyo announced the establishment of a new commercialization unit effective April 1, consolidating and reorganizing its global commercialization structure, with Ken Keller appointed as Chief Commercialization Officer.
Source:
- nikkei.com
Aug 18, 2026, 03:34 UTC
Daiichi Sankyo announced positive results from a global Phase 3 clinical trial of its cancer drug Enhertu for first-line treatment of HER2-mutant non-small cell lung cancer, showing statistically significant and clinically meaningful improvement in the primary endpoint with no new safety concerns.
Source:
Aug 12, 2026, 07:36 UTC
Daiichi Sankyo announced that its drug Enhertu (trastuzumab deruxtecan) in combination with pertuzumab received approval in China for first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults.
Jul 14, 2026, 11:00 UTC
FRONTEO and Daiichi Sankyo jointly develop a predictive model that automatically extracts toxicological interpretations from toxicity study reports, presented at the 53rd Annual Meeting of the Japanese Society of Toxicology.
Source:
- s.kabutan.jp
- s.kabutan.jp

4568.T

The National Institute for Health and Care Excellence (NICE) issued a positive recommendation for reimbursement in England of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as monotherapy for adults with unresectable or metastatic HER2 Low breast cancer.

Fortis Healthcare filed a special leave petition in the Supreme Court against a Delhi High Court order dated August 31 directing a forensic audit into alleged asset erosion by its former promoters during Daiichi Sankyo's enforcement proceedings.

The Tokyo District Court dismissed all claims by an IHH Healthcare subsidiary seeking about 203.3 billion yen in damages from Daiichi Sankyo over a halted tender offer for an Indian healthcare company.

Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.

Daiichi Sankyo announced that the European Union granted a partial change approval for the combination therapy of Enhertu and pertuzumab as first-line treatment for breast cancer patients.

The Delhi High Court ordered a forensic audit into the dissipation of Fortis shares and assets linked to former Fortis promoters Malvinder Mohan Singh and Shivinder Mohan Singh in the Daiichi Sankyo enforcement case, appointing S Ramanand Aiyar & Co. as the forensic auditor.

Daiichi Sankyo announced the establishment of a new commercialization unit effective April 1, consolidating and reorganizing its global commercialization structure, with Ken Keller appointed as Chief Commercialization Officer.

Daiichi Sankyo announced positive results from a global Phase 3 clinical trial of its cancer drug Enhertu for first-line treatment of HER2-mutant non-small cell lung cancer, showing statistically significant and clinically meaningful improvement in the primary endpoint with no new safety concerns.

Daiichi Sankyo announced that its drug Enhertu (trastuzumab deruxtecan) in combination with pertuzumab received approval in China for first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults.

FRONTEO and Daiichi Sankyo jointly develop a predictive model that automatically extracts toxicological interpretations from toxicity study reports, presented at the 53rd Annual Meeting of the Japanese Society of Toxicology.